Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Pathophysiology Research Template

Target Disease

• Disease Name: 3-Hydroxy-3-Methylglutaric Aciduria
• MONDO ID: (if available)
• Category: Genetic

Research Objectives

Please provide a comprehensive research report on the pathophysiology of 3-Hydroxy-3-Methylglutaric Aciduria. Focus on the molecular and cellular mechanisms underlying disease progression.

Required Information

1. Core Pathophysiology

• What are the primary pathophysiological mechanisms?
• What molecular pathways are dysregulated?
• What cellular processes are affected?

2. Key Molecular Players

• Genes/Proteins: Which genes are causally involved or implicated?
• Chemical Entities: What metabolites, drugs, or small molecules are relevant?
• Cell Types: Which cell types are primarily affected?
• Anatomical Locations: Which tissues/organs are involved?

3. Biological Processes (for GO annotation)

• What biological processes (GO terms) are disrupted?
• Consider: signaling pathways, metabolic processes, cellular responses, transport, etc.

4. Cellular Components

• Where in the cell do key processes occur?
• Consider: organelles, membrane compartments, extracellular space, etc.

5. Disease Progression

• What is the sequence of events from initial trigger to clinical manifestation?
• Are there distinct stages or phases?

6. Phenotypic Manifestations

• What are the key clinical phenotypes?
• How do they relate to the underlying mechanisms?

Citation Requirements

• Cite primary literature (PMID preferred) for all mechanistic claims
• Prioritize recent reviews and landmark papers
• Include direct quotes where possible to support key statements

Output Format

Structure your response as a narrative that could be used to populate a disease knowledge base entry with: - Pathophysiology description - Gene/protein annotations with ontology terms (HGNC, GO) - Phenotype associations (HP terms) - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Evidence items with PMIDs

Title: Pathophysiology Research Report — 3‑Hydroxy‑3‑Methylglutaric Aciduria (HMG‑CoA Lyase Deficiency)

Publication window emphasized: 2023–2024 (with essential foundational mechanistic and cohort sources where needed).

1. Disease definition, identifiers, and core biochemical defect

Disease concept. “3‑Hydroxy‑3‑methylglutaric aciduria/acidemia” in clinical practice corresponds to 3‑hydroxy‑3‑methylglutaryl‑CoA lyase deficiency (HMGCLD/HMGLD), an autosomal recessive inborn error affecting ketogenesis and leucine catabolism. The key feature is inability to generate ketone bodies during catabolic stress, coupled with accumulation of characteristic leucine‑derived metabolites (organic acids and acyl‑CoA intermediates). (devanapalli2023useofsodium pages 1-3, grunert20203hydroxy3methylglutarylcoenzymealyase pages 1-2)

OMIM/MIM. The disorder is reported as MIM/OMIM 246450 in a systematic review and in a large clinical cohort description. (grunert20203hydroxy3methylglutarylcoenzymealyase pages 1-2, alfadhel2022hmgcoalyasedeficiency pages 1-2)

Causal gene/protein. Biallelic pathogenic variants in HMGCL cause deficiency of mitochondrial 3‑hydroxy‑3‑methylglutaryl‑CoA lyase (EC 4.1.3.4). HMGCL catalyzes cleavage of HMG‑CoA to acetyl‑CoA and acetoacetate, “the final step of ketogenesis and leucine degradation.” (devanapalli2023useofsodium pages 1-3, devanapalli2023useofsodium pages 3-5)

Key biochemical signature (clinical definition). Typical biochemical hallmarks include: (i) absent/low ketones during crises (hypoketotic or non‑ketotic hypoglycemia) and (ii) urine organic acids showing elevated 3‑hydroxy‑3‑methylglutaric acid (HMG), 3‑methylglutaconic acid (3MGC), 3‑methylglutaric acid (3MGL), and 3‑hydroxyisovaleric acid (3‑HIVA), often with elevated acylcarnitine C5‑OH (3‑hydroxyisovalerylcarnitine) in plasma/newborn screening. (devanapalli2023useofsodium pages 1-3, devanapalli2023useofsodium pages 3-5)

1. Core pathophysiology (molecular and cellular mechanisms)

2.1 Primary mechanism: ketogenesis failure → energy failure in brain/heart during catabolic stress

HMGCL is required for hepatic ketone production (acetoacetate and 3‑hydroxybutyrate), which supplies energy to extrahepatic tissues during fasting/illness, particularly brain. Accordingly, acute crises feature hypoglycemia with inadequate ketone availability and metabolic acidosis. (grunert20203hydroxy3methylglutarylcoenzymealyase pages 1-2, grunert20203hydroxy3methylglutarylcoenzymealyase pages 2-4)

Clinical trigger context and progression. In the compiled 211‑case systematic review, >95% had at least one metabolic decompensation; onset clustered in infancy with ~42% neonatal onset. Crises commonly include vomiting, lethargy/coma, tachypnea/apnoea, seizures, and hepatomegaly, with laboratory findings of severe hypoglycemia, metabolic acidosis, and hyperammonemia. (grunert20203hydroxy3methylglutarylcoenzymealyase pages 2-4)

2.2 Primary mechanism: leucine catabolic block → accumulation of organic acids and acyl‑CoA stress

Blockade at HMG‑CoA lyase causes upstream accumulation of leucine‑related metabolites. A 2023 longitudinal cohort emphasized illness‑driven leucine flux, stating “3‑HMG must arise from both fat and leucine oxidation,” and reporting higher leucine turnover and greater urinary excretion of 3MGC and 3‑HIVA during illness than fasting, implying leucine‑derived toxicity is prominent under inflammatory/catabolic stress. (thompson2023treatmentofhmgcoa pages 5-6)

2.3 Secondary mechanism: acyl‑CoA / free CoA disequilibrium and mitochondrial dysfunction

Acyl‑CoA disruption as a mechanistic driver. A foundational liver‑specific Hmgcl knockout mouse model demonstrated that chronic deficiency and acute crises yield “distinct abnormal liver acyl‑CoA patterns,” and that leucine metabolite loading (2‑ketoisocaproate, KIC) increases leucine‑related acyl‑CoAs while reducing acetyl‑CoA, with hepatocyte mitochondrial swelling after KIC—direct evidence of mitochondrial injury in crisis states. (gauthier2013aliverspecificdefect pages 1-2)

Hyperammonemia mechanism (acetyl‑CoA dependence of urea cycle activation). In the same mouse model, KIC‑induced hyperammonemia improved with carglumate, “which substitutes for the product of an acetyl‑CoA‑dependent reaction essential for urea cycle function,” supporting an acyl‑CoA/acetyl‑CoA–linked mechanism for hyperammonemia in HMGCLD. (gauthier2013aliverspecificdefect pages 1-2)

Clinical inference: CoA trapping and acetyl‑CoA depletion can simultaneously compromise ketogenesis, gluconeogenesis, and urea cycling, producing the characteristic triad of hypoketotic hypoglycemia + acidosis + hyperammonemia in severe crises. (gauthier2013aliverspecificdefect pages 1-2, grunert20203hydroxy3methylglutarylcoenzymealyase pages 2-4)

2.4 2024 mechanistic advance: non‑enzymatic mitochondrial protein acylation (3MGCylation)

A 2024 mechanistic study proposed a specific chemical toxicity mechanism via trans‑3‑methylglutaconyl‑CoA (trans‑3MGC‑CoA). The study describes formation of a reactive cis‑3MGC anhydride; importantly: “The anhydride is chemically reactive… it reacts with lysine side chain amino groups to acylate nearby proteins.” (jennings2024factorsaffectingnonenzymatic pages 11-12)

In vivo relevance is supported by liver‑specific HMGCL knockout mice: “Relative protein 3MGCylation levels were much higher in liver‑specific HMGCL KO mouse liver mitochondrial samples compared with the corresponding WT mouse samples,” and “KIC loading led to increased protein 3MGCylation levels,” linking leucine flux to mitochondrial protein lysine acylation. (jennings2024factorsaffectingnonenzymatic pages 11-12)

Interpretation/expert analysis. This frames HMGCLD not only as “energy deficiency” but also as a disorder of reactive metabolite chemistry in the mitochondrial matrix, potentially altering enzyme networks by covalent modification (a hypothesis the authors identify as requiring future protein‑target identification and functional studies). (jennings2024factorsaffectingnonenzymatic pages 11-12)

2.5 2024 experimental neurotoxicity: HMG disrupts redox, bioenergetics, and mitochondrial dynamics in neonatal brain

A 2024 neonatal rat brain model directly tested toxicity of the major accumulating metabolite HMG, finding oxidative stress and bioenergetic defects, plus altered mitochondrial fission. Key statistically supported findings include:

• Citric acid cycle / respiratory chain: cortical SDH reduced (t(6)=4.899; p<0.01); cortical complexes II–III (t(6)=6.877; p<0.05) and IV (t(6)=3.329; p<0.05) reduced; striatal citrate synthase reduced (t(6)=6.460; p<0.05) and SDH reduced (t(6)=2.151; p<0.01); striatal complex IV reduced (t(6)=7.935; p<0.01). (silveira20243hydroxy3methylglutaricaciddisrupts pages 5-9)

• Mitochondrial dynamics: DRP1 content markedly increased (t(10)=16.88; p<0.001), consistent with increased mitochondrial fission. (silveira20243hydroxy3methylglutaricaciddisrupts pages 5-9)

These results connect a patient biomarker (HMG accumulation) to plausible cellular injury pathways (ETC impairment, ROS‑linked redox imbalance, and mitochondrial network fragmentation), aligning with clinical neurodevelopmental vulnerability in early life. (silveira20243hydroxy3methylglutaricaciddisrupts pages 1-2, silveira20243hydroxy3methylglutaricaciddisrupts pages 5-9)

Figures providing experimental data. The study’s results are visually summarized in the main figures: antioxidant defenses (Figures 1–2), TCA enzymes and respiratory chain activities (Figures 3–4), and mitochondrial dynamics proteins (Figure 5). (silveira20243hydroxy3methylglutaricaciddisrupts media cdb163bd, silveira20243hydroxy3methylglutaricaciddisrupts media f967e15a, silveira20243hydroxy3methylglutaricaciddisrupts media cd280ab9)

1. Key molecular players (genes/proteins, metabolites, cell types, anatomy)

3.1 Genes/proteins

Causal gene: HMGCL (mitochondrial HMG‑CoA lyase). (devanapalli2023useofsodium pages 1-3, grunert20203hydroxy3methylglutarylcoenzymealyase pages 1-2)

Mechanistically implicated proteins/processes: • Mitochondrial respiratory chain complexes (II–III, IV) and TCA enzymes (SDH, CS) affected by HMG exposure in brain tissue. (silveira20243hydroxy3methylglutaricaciddisrupts pages 5-9) • DRP1 (DNM1L protein; mitochondrial fission regulator) increased with HMG exposure. (silveira20243hydroxy3methylglutaricaciddisrupts pages 5-9) • AUH (3MGC‑CoA hydratase) implicated in diverting trans‑3MGC‑CoA away from reactive anhydride formation; the 2024 study shows AUH reduces (attenuates) 3MGCylation signal. (jennings2024factorsaffectingnonenzymatic pages 11-12)

Genotype–phenotype and population genetics. In the 62‑patient Saudi cohort, a founder HMGCL variant c.122G>A (p.Arg41Gln) accounted for 77.41% of affected individuals, illustrating strong population structure and potential genotype clustering of clinical risk. (alfadhel2022hmgcoalyasedeficiency pages 1-2)

3.2 Chemical entities (metabolites, drugs, small molecules)

Key metabolites/biomarkers: • 3‑hydroxy‑3‑methylglutaric acid (HMG) (major accumulating metabolite in patients; modeled as neurotoxin in 2024 rat study). (silveira20243hydroxy3methylglutaricaciddisrupts pages 1-2, silveira20243hydroxy3methylglutaricaciddisrupts pages 5-9) • 3‑methylglutaconic acid (3MGC), 3‑methylglutaric acid (3MGL), 3‑hydroxyisovaleric acid (3‑HIVA). (devanapalli2023useofsodium pages 3-5, silveira20243hydroxy3methylglutaricaciddisrupts pages 1-2) • HMG‑CoA, acetyl‑CoA, acetoacetate (reaction substrates/products). (devanapalli2023useofsodium pages 1-3) • trans‑3MGC‑CoA and reactive cis‑3MGC anhydride; protein 3MGCylation adducts. (jennings2024factorsaffectingnonenzymatic pages 11-12) • 2‑ketoisocaproate (KIC) as leucine‑catabolic stressor in mouse/mitochondrial acylation models. (gauthier2013aliverspecificdefect pages 1-2, jennings2024factorsaffectingnonenzymatic pages 11-12)

Therapeutically relevant small molecules: • Sodium D,L‑3‑hydroxybutyrate (exogenous ketone salt) used as adjunct therapy to bypass impaired ketogenesis. (devanapalli2023useofsodium pages 1-3, devanapalli2023useofsodium pages 7-10) • L‑carnitine used in long‑term management; commonly prescribed in reviewed cohorts. (devanapalli2023useofsodium pages 7-10) • Carglumate used experimentally to rescue hyperammonemia via acetyl‑CoA–dependent urea cycle activation proxy (mouse model). (gauthier2013aliverspecificdefect pages 1-2)

3.3 Cell types and tissues (CL/UBERON-style)

Dominant vulnerable organs: • Liver (ketogenesis, acyl‑CoA perturbation, hyperammonemia mechanism; hepatocyte mitochondrial swelling in crisis model). (gauthier2013aliverspecificdefect pages 1-2) • Brain (white matter/basal ganglia abnormalities clinically; cortex and striatum show redox/ETC and mitochondrial fission changes in experimental HMG exposure). (silveira20243hydroxy3methylglutaricaciddisrupts pages 1-2, silveira20243hydroxy3methylglutaricaciddisrupts pages 5-9) • Heart (clinically reported cardiomyopathy in systematic review; mechanistic rationale: reliance on ketone bodies in fasting/stress). (devanapalli2023useofsodium pages 7-10, grunert20203hydroxy3methylglutarylcoenzymealyase pages 2-4)

At the cellular compartment level, the 2024 3MGCylation mechanism is explicitly mitochondrial-matrix–centric (“protein-rich environment of the mitochondrial matrix”). (jennings2024factorsaffectingnonenzymatic pages 11-12)

1. Biological processes and cellular components (GO-oriented narrative)

Disrupted biological processes (examples of GO-term-style concepts): • Ketone body metabolic process / ketogenesis (failure of acetoacetate and 3‑hydroxybutyrate production). (devanapalli2023useofsodium pages 1-3, grunert20203hydroxy3methylglutarylcoenzymealyase pages 1-2) • Branched‑chain amino acid catabolic process (leucine degradation). (devanapalli2023useofsodium pages 1-3, grunert20203hydroxy3methylglutarylcoenzymealyase pages 1-2) • Mitochondrial electron transport and oxidative phosphorylation (complex II–III and IV activity reductions in cortex; complex IV reduction in striatum). (silveira20243hydroxy3methylglutaricaciddisrupts pages 5-9) • Tricarboxylic acid cycle (citrate synthase and succinate dehydrogenase decreases in striatum; SDH decrease in cortex). (silveira20243hydroxy3methylglutaricaciddisrupts pages 5-9) • Redox homeostasis / oxidative stress response (disturbed antioxidant defenses after HMG exposure). (silveira20243hydroxy3methylglutaricaciddisrupts pages 1-2, silveira20243hydroxy3methylglutaricaciddisrupts pages 5-9) • Protein lysine acylation (non‑enzymatic 3MGCylation) and reactive metabolite chemistry in mitochondria. (jennings2024factorsaffectingnonenzymatic pages 11-12) • Mitochondrial fission (increased DRP1). (silveira20243hydroxy3methylglutaricaciddisrupts pages 5-9)

Key cellular components (examples of GO CC–style concepts): • Mitochondrial matrix (site of 3MGC anhydride formation and protein acylation). (jennings2024factorsaffectingnonenzymatic pages 11-12) • Mitochondrial respiratory chain complexes / inner mitochondrial membrane (functional outputs altered in HMG exposure model). (silveira20243hydroxy3methylglutaricaciddisrupts pages 5-9)

1. Disease progression model (trigger → molecular events → cellular dysfunction → clinical manifestations)

Stage 0 (baseline/intercritical). Many patients may be clinically well between episodes; however, biochemical perturbations (abnormal metabolite excretion, acylcarnitines) persist and may contribute to chronic neurologic sequelae in a subset. (grunert20203hydroxy3methylglutarylcoenzymealyase pages 2-4, alfadhel2022hmgcoalyasedeficiency pages 1-2)

Stage 1 (trigger). Catabolic stress (fasting, intercurrent illness) increases reliance on ketogenesis and leucine/fat oxidation; in HMGCLD, ketone production fails and leucine‑derived intermediates accumulate. (devanapalli2023useofsodium pages 1-3, grunert20203hydroxy3methylglutarylcoenzymealyase pages 2-4)

Stage 2 (metabolic crisis). Combined effects manifest as hypoketotic/non‑ketotic hypoglycemia + metabolic acidosis; hyperammonemia can become severe (reports >1000–2000 µmol/L). (grunert20203hydroxy3methylglutarylcoenzymealyase pages 2-4)

Stage 3 (cellular injury). Mechanistically supported injury pathways include acyl‑CoA/acetyl‑CoA imbalance (affecting gluconeogenesis and urea cycle activation), mitochondrial dysfunction and swelling, oxidative stress, impaired respiratory chain function, and mitochondrial network fragmentation; additionally, reactive metabolite–driven protein acylation (3MGCylation) may damage mitochondrial proteostasis/function. (gauthier2013aliverspecificdefect pages 1-2, silveira20243hydroxy3methylglutaricaciddisrupts pages 5-9, jennings2024factorsaffectingnonenzymatic pages 11-12)

Stage 4 (clinical outcomes). Acute encephalopathy/seizures/coma may occur, with long‑term sequelae including developmental delay, white matter abnormalities, epilepsy, and in some cases cardiomyopathy or liver failure. (devanapalli2023useofsodium pages 1-3, alfadhel2022hmgcoalyasedeficiency pages 1-2, grunert20203hydroxy3methylglutarylcoenzymealyase pages 2-4)

1. Phenotypic manifestations and quantitative epidemiology/statistics

6.1 Systematic review (211 reported cases; authoritative synthesis)

A 2020 Orphanet Journal of Rare Diseases systematic review compiled 211 published patients: • Acute metabolic decompensation: 95.3% (163/171 with available data) had ≥1 crisis. (grunert20203hydroxy3methylglutarylcoenzymealyase pages 2-4) • Neonatal onset: 42.4% (70/165 with onset data). (grunert20203hydroxy3methylglutarylcoenzymealyase pages 2-4) • Mortality: 16.1% (34/211). (grunert20203hydroxy3methylglutarylcoenzymealyase pages 2-4) • Neurologic outcome: 62.6% normal development among those with available outcome data. (grunert20203hydroxy3methylglutarylcoenzymealyase pages 1-2) • Severe hyperammonemia: reports >1000 µmol/L and one >2000 µmol/L requiring dialysis. (grunert20203hydroxy3methylglutarylcoenzymealyase pages 2-4)

6.2 Large contemporary regional cohort (Saudi Arabia; n=62)

A 2022 62‑patient Saudi cohort (molecularly confirmed) provides phenotype frequencies: • Hypoglycemia at diagnosis: 61.29% (38/62). (alfadhel2022hmgcoalyasedeficiency pages 1-2) • Metabolic acidosis: 79.03% (49/62). (alfadhel2022hmgcoalyasedeficiency pages 1-2) • Neonatal onset: 43.54% (27/62). (alfadhel2022hmgcoalyasedeficiency pages 1-2) • Seizures: 27.41% (17/62); learning disability: 24.14% (15/62). (alfadhel2022hmgcoalyasedeficiency pages 1-2) • MRI white matter hyperintensities: 25.80% (16/62). (alfadhel2022hmgcoalyasedeficiency pages 1-2) • Genetics: founder variant c.122G>A (p.Arg41Gln) in 77.41% (48/62). (alfadhel2022hmgcoalyasedeficiency pages 1-2)

6.3 Selected recent clinical biomarker statistics (2023 case report)

In a 2023 sibling case report, representative screening/diagnostic biomarker magnitudes were provided: • Newborn screen C5‑OH 2.8 µmol/L (reference <1). (devanapalli2023useofsodium pages 3-5) • Plasma C5‑OH 2.59 µmol/L (reference <0.15). (devanapalli2023useofsodium pages 3-5) • Example metabolic crisis acid–base values: pH 7.2, HCO3 9, base excess −17. (devanapalli2023useofsodium pages 3-5)

1. Recent developments and latest research (prioritized 2023–2024)

7.1 2023–2024 management evolution: exogenous ketone therapy and refined dietary emergency plans

Exogenous ketone (sodium D,L‑3‑hydroxybutyrate; S‑DL‑3OHB). A 2023 report of two siblings concluded: “S‑DL‑3OHB therapy is a well‑tolerated and effective therapeutic option for this disorder,” explicitly motivated by the loss of ketone supply to brain and heart during starvation. (devanapalli2023useofsodium pages 1-3)

Real‑world use in a 2023 Australian longitudinal cohort (Nutrients; 10 cases): • “Four patients have used high‑dose S‑DL‑3OHB (900 mg/kg/day) as part of their acute management plan,” and acute care emphasized carbohydrate rescue (maltodextrin-based plans) and avoidance of catabolism. (thompson2023treatmentofhmgcoa pages 4-5) • The cohort also reports long intercritical stability in some adults (no acute presentation for 11–22 years), consistent with efficacy of anticipatory management once patients reach adulthood and/or have stable care routines. (thompson2023treatmentofhmgcoa pages 4-5)

Dietary management and emergency protocols. The 2023 cohort reported emergency carbohydrate plans “based on 120% estimated energy requirement” and highlighted that illness (more than fasting alone) often precipitates severe/protracted episodes, supporting the modern emphasis on early sick‑day carbohydrate protocols. (thompson2023treatmentofhmgcoa pages 5-6)

7.2 2024 mechanistic shift: reactive metabolite chemistry in mitochondria (3MGCylation) as a candidate disease driver

The 2024 Metabolites study provides a new mechanistic concept: trans‑3MGC‑CoA instability creates a “chemical sink” that both preserves free CoA and yields toxic outputs (3MGC acid and protein 3MGCylation) in a mitochondrial matrix context. (jennings2024factorsaffectingnonenzymatic pages 11-12)

Expert interpretation. If validated in human tissues, 3MGCylation could help explain “non‑linear” phenotype severity and tissue specificity (e.g., liver vulnerability during leucine load; possible links to cardiomyopathy), and it highlights potential new therapeutic directions (e.g., reducing trans‑3MGC‑CoA formation, enhancing detoxifying hydration steps, or promoting deacylation), but the authors emphasize open questions on targeted proteins and functional consequences. (jennings2024factorsaffectingnonenzymatic pages 11-12)

7.3 2024 experimental neurobiology: identifying concrete mitochondrial targets of HMG

The 2024 Biomedicines study adds quantitative support that HMG itself can disrupt key mitochondrial nodes (SDH; complexes II–III and IV; DRP1-driven fission), aligning with the clinical predominance of neurologic manifestations early in life. (silveira20243hydroxy3methylglutaricaciddisrupts pages 5-9, silveira20243hydroxy3methylglutaricaciddisrupts pages 1-2)

1. Current applications and real-world implementations

8.1 Newborn screening and diagnostic workflows

Newborn screening. Tandem mass spectrometry (MS/MS) screening using elevated C5‑OH is described as a diagnostic route in the 62‑patient cohort, with confirmation by urine organic acids and molecular testing. (alfadhel2022hmgcoalyasedeficiency pages 1-2)

Confirmatory testing. Diagnosis is established by characteristic urinary organic acids plus abnormal acylcarnitines and confirmed by enzyme assays in patient cells and/or HMGCL mutation analysis. (grunert20203hydroxy3methylglutarylcoenzymealyase pages 1-2)

8.2 Acute crisis management (implemented clinically)

Principles reported in 2023 longitudinal and case studies include: • Rapid provision of glucose (IV dextrose and/or frequent oral carbohydrate such as maltodextrin) to suppress catabolism and prevent hypoglycemia. (thompson2023treatmentofhmgcoa pages 5-6, thompson2023treatmentofhmgcoa pages 4-5) • Avoidance of fasting, protein/leucine restriction, and frequently fat restriction in some protocols. (devanapalli2023useofsodium pages 7-10, thompson2023treatmentofhmgcoa pages 6-8) • Adjunct exogenous ketone therapy (S‑DL‑3OHB) during acute decompensation and sometimes long-term adjunct use. (thompson2023treatmentofhmgcoa pages 4-5, devanapalli2023useofsodium pages 1-3)

8.3 Long-term management and monitoring

Long-term management strategies widely used in contemporary practice (per 2023 review/case report) include: protein/leucine restriction, avoidance of fasting, carnitine supplementation (used in 78% in reviewed cases), and individualized use of exogenous ketone therapy; monitoring includes acylcarnitines/urine organic acids and clinical neurodevelopment/cardiac surveillance. (devanapalli2023useofsodium pages 7-10)

1. Evidence items (mechanistic claims with direct quotes, URLs, and publication dates)

Key evidence quote 1 (3MGCylation mechanism; publication date: 2024‑07; URL: https://doi.org/10.3390/metabo14080421): “The anhydride is chemically reactive… it reacts with lysine side chain amino groups to acylate nearby proteins.” (jennings2024factorsaffectingnonenzymatic pages 11-12)

Key evidence quote 2 (HMGCLD definition/energy rationale; publication date: 2020‑02; URL: https://doi.org/10.1186/s13023-020-1319-7): Ketone bodies are “an important source of energy for extrahepatic organs, in particular of the brain,” and crises feature “hypoglycemia and metabolic acidosis.” (grunert20203hydroxy3methylglutarylcoenzymealyase pages 1-2)

Key evidence quote 3 (acyl‑CoA mechanism for hyperammonemia; publication date: 2013‑07‑05; URL: https://doi.org/10.1371/journal.pone.0060581): “KIC‑induced hyperammonemia improved following administration of carglumate… demonstrating an acyl‑CoA‑related mechanism for this complication.” (gauthier2013aliverspecificdefect pages 1-2)

1. Structured knowledge-base annotation (term strings; IDs not always provided in sources)

10.1 Pathophysiology description (knowledge-base ready)

HMGCLD is a mitochondrial ketogenesis/leucine-catabolism defect caused by biallelic HMGCL variants, resulting in failure to produce ketone bodies (acetoacetate, D‑3‑hydroxybutyrate) during catabolic stress and accumulation of leucine-derived organic acids and acyl‑CoA intermediates (HMG, 3MGC, 3MGL, 3‑HIVA; trans‑3MGC‑CoA). Acute illness/fasting triggers energy failure and intoxication, producing hypoketotic hypoglycemia, metabolic acidosis, and hyperammonemia; mechanistically, hepatic acyl‑CoA disturbances and acetyl‑CoA depletion can impair gluconeogenesis and urea cycle activation (carglumate responsiveness). Accumulating metabolites can also directly cause mitochondrial redox and respiratory chain dysfunction and perturb mitochondrial dynamics in the developing brain (SDH and complex II–III/IV inhibition; increased DRP1), contributing to seizures, developmental delay, and white matter disease. A 2024 mechanistic advance proposes reactive metabolite chemistry (cis‑3MGC anhydride) leading to mitochondrial protein lysine acylation (3MGCylation) as a potentially toxic process linking leucine flux to mitochondrial dysfunction. (devanapalli2023useofsodium pages 1-3, gauthier2013aliverspecificdefect pages 1-2, silveira20243hydroxy3methylglutaricaciddisrupts pages 5-9, jennings2024factorsaffectingnonenzymatic pages 11-12)

10.2 Gene/protein annotations

• HMGCL — 3‑hydroxy‑3‑methylglutaryl‑CoA lyase; mitochondrial enzyme; catalyzes HMG‑CoA → acetyl‑CoA + acetoacetate (ketogenesis and leucine degradation). (devanapalli2023useofsodium pages 1-3)

10.3 Candidate disrupted GO Biological Processes (term strings)

• Ketone body metabolic process / ketogenesis (devanapalli2023useofsodium pages 1-3, grunert20203hydroxy3methylglutarylcoenzymealyase pages 1-2) • Leucine catabolic process / branched-chain amino acid catabolism (devanapalli2023useofsodium pages 1-3, grunert20203hydroxy3methylglutarylcoenzymealyase pages 1-2) • Tricarboxylic acid cycle (succinate dehydrogenase; citrate synthase) (silveira20243hydroxy3methylglutaricaciddisrupts pages 5-9) • Mitochondrial electron transport / oxidative phosphorylation (complex II–III, IV) (silveira20243hydroxy3methylglutaricaciddisrupts pages 5-9) • Cellular redox homeostasis / oxidative stress response (silveira20243hydroxy3methylglutaricaciddisrupts pages 1-2, silveira20243hydroxy3methylglutaricaciddisrupts pages 5-9) • Protein lysine acylation (3MGCylation; non-enzymatic) (jennings2024factorsaffectingnonenzymatic pages 11-12) • Mitochondrial fission (DRP1 increase) (silveira20243hydroxy3methylglutaricaciddisrupts pages 5-9)

10.4 Cellular components (term strings)

• Mitochondrial matrix (protein-rich environment for 3MGC anhydride reactions) (jennings2024factorsaffectingnonenzymatic pages 11-12) • Mitochondrial inner membrane / respiratory chain complexes (functional impairment) (silveira20243hydroxy3methylglutaricaciddisrupts pages 5-9)

10.5 Phenotype associations (HP-style term strings) with evidence

• Hypoketotic/non‑ketotic hypoglycemia (devanapalli2023useofsodium pages 1-3, alfadhel2022hmgcoalyasedeficiency pages 1-2) • Metabolic acidosis (alfadhel2022hmgcoalyasedeficiency pages 1-2, grunert20203hydroxy3methylglutarylcoenzymealyase pages 2-4) • Hyperammonemia (grunert20203hydroxy3methylglutarylcoenzymealyase pages 2-4, gauthier2013aliverspecificdefect pages 1-2) • Seizures/status epilepticus (alfadhel2022hmgcoalyasedeficiency pages 1-2, devanapalli2023useofsodium pages 3-5) • Developmental delay / learning disability (alfadhel2022hmgcoalyasedeficiency pages 1-2) • White matter abnormalities / periventricular hyperintensities (alfadhel2022hmgcoalyasedeficiency pages 1-2) • Hepatic dysfunction / transaminase elevation; occasional liver failure (thompson2023treatmentofhmgcoa pages 5-6, grunert20203hydroxy3methylglutarylcoenzymealyase pages 2-4) • Cardiomyopathy (rare but reported; fatal cases in systematic review) (grunert20203hydroxy3methylglutarylcoenzymealyase pages 2-4)

10.6 Cell type involvement (CL-style term strings)

• Hepatocytes (liver-specific KO mechanistic model; ketogenesis, acyl‑CoA patterns) (gauthier2013aliverspecificdefect pages 1-2) • Neurons and glia in cortex/striatum (modeled by region-specific brain biochemical effects; neurodevelopment impairment) (silveira20243hydroxy3methylglutaricaciddisrupts pages 5-9)

10.7 Anatomical locations (UBERON-style term strings)

• Liver (ketogenesis; acyl‑CoA disturbances; hyperammonemia mechanism) (gauthier2013aliverspecificdefect pages 1-2) • Brain: cerebral cortex; striatum; white matter; basal ganglia (clinical MRI and experimental model focus) (silveira20243hydroxy3methylglutaricaciddisrupts pages 1-2, silveira20243hydroxy3methylglutaricaciddisrupts pages 5-9) • Heart (clinical cardiomyopathy reports; ketone reliance rationale) (grunert20203hydroxy3methylglutarylcoenzymealyase pages 2-4, devanapalli2023useofsodium pages 1-3)

10.8 Chemical entities (CHEBI-style term strings)

• 3‑hydroxy‑3‑methylglutaric acid (HMG) (silveira20243hydroxy3methylglutaricaciddisrupts pages 1-2) • 3‑methylglutaconic acid (3MGC) (devanapalli2023useofsodium pages 3-5) • 3‑methylglutaric acid (3MGL) (devanapalli2023useofsodium pages 3-5) • 3‑hydroxyisovaleric acid (3‑HIVA) (devanapalli2023useofsodium pages 3-5) • 3‑hydroxyisovalerylcarnitine (C5‑OH) (devanapalli2023useofsodium pages 3-5) • HMG‑CoA; acetyl‑CoA; acetoacetate (devanapalli2023useofsodium pages 1-3) • trans‑3MGC‑CoA; cis‑3MGC anhydride; 3MGCylated proteins (jennings2024factorsaffectingnonenzymatic pages 11-12) • D,L‑3‑hydroxybutyrate (sodium salt; S‑DL‑3OHB) (devanapalli2023useofsodium pages 1-3) • 2‑ketoisocaproate (KIC) (gauthier2013aliverspecificdefect pages 1-2) • Carglumate (N‑carbamyl‑L‑glutamate) (gauthier2013aliverspecificdefect pages 1-2) • L‑carnitine (devanapalli2023useofsodium pages 7-10)

1. Limitations and evidence gaps (important for knowledge-base curation)

• PMIDs: Several recent open-access MDPI/OAE articles and some excerpts did not contain PMIDs in the retrieved text segments; thus, citations here are DOI/URL-based for those sources. (silveira20243hydroxy3methylglutaricaciddisrupts pages 1-2, jennings2024factorsaffectingnonenzymatic pages 11-12, devanapalli2023useofsodium pages 1-3) • MONDO ID was not recoverable from the retrieved sources in this run; OMIM/MIM 246450 is explicitly supported. (grunert20203hydroxy3methylglutarylcoenzymealyase pages 1-2, alfadhel2022hmgcoalyasedeficiency pages 1-2) • Many mechanistic hypotheses (e.g., 3MGCylation functional consequences, best biomarkers to titrate exogenous ketone therapy) are explicitly framed by authors as requiring further study, highlighting an active research frontier rather than settled mechanisms. (jennings2024factorsaffectingnonenzymatic pages 11-12, devanapalli2023useofsodium pages 7-10)

References

1. (devanapalli2023useofsodium pages 1-3): Beena Devanapalli, Adviye Ayper Tolun, Won-Tae Kim, Tiffany Wotton, Susan Thompson, and Shanti Balasubramaniam. Use of sodium d, l-3-hydroxybutyrate as adjunct therapy in two siblings with hmg-coa lyase deficiency. Journal of Translational Genetics and Genomics, 7:186-95, Sep 2023. URL: https://doi.org/10.20517/jtgg.2023.12, doi:10.20517/jtgg.2023.12. This article has 0 citations.

2. (grunert20203hydroxy3methylglutarylcoenzymealyase pages 1-2): Sarah C. Grünert and Jörn Oliver Sass. 3-hydroxy-3-methylglutaryl-coenzyme a lyase deficiency: one disease - many faces. Orphanet Journal of Rare Diseases, Feb 2020. URL: https://doi.org/10.1186/s13023-020-1319-7, doi:10.1186/s13023-020-1319-7. This article has 41 citations and is from a peer-reviewed journal.

3. (alfadhel2022hmgcoalyasedeficiency pages 1-2): Majid Alfadhel, Basma Abadel, Hind Almaghthawi, Muhammad Umair, Zuhair Rahbeeni, Eissa Faqeih, Mohammed Almannai, Ali Alasmari, Mohammed Saleh, Wafaa Eyaid, Ahmed Alfares, and Fuad Al Mutairi. Hmg-coa lyase deficiency: a retrospective study of 62 saudi patients. Frontiers in Genetics, May 2022. URL: https://doi.org/10.3389/fgene.2022.880464, doi:10.3389/fgene.2022.880464. This article has 19 citations and is from a peer-reviewed journal.

4. (devanapalli2023useofsodium pages 3-5): Beena Devanapalli, Adviye Ayper Tolun, Won-Tae Kim, Tiffany Wotton, Susan Thompson, and Shanti Balasubramaniam. Use of sodium d, l-3-hydroxybutyrate as adjunct therapy in two siblings with hmg-coa lyase deficiency. Journal of Translational Genetics and Genomics, 7:186-95, Sep 2023. URL: https://doi.org/10.20517/jtgg.2023.12, doi:10.20517/jtgg.2023.12. This article has 0 citations.

5. (grunert20203hydroxy3methylglutarylcoenzymealyase pages 2-4): Sarah C. Grünert and Jörn Oliver Sass. 3-hydroxy-3-methylglutaryl-coenzyme a lyase deficiency: one disease - many faces. Orphanet Journal of Rare Diseases, Feb 2020. URL: https://doi.org/10.1186/s13023-020-1319-7, doi:10.1186/s13023-020-1319-7. This article has 41 citations and is from a peer-reviewed journal.

6. (thompson2023treatmentofhmgcoa pages 5-6): Susan Thompson, Ashley Hertzog, Arthavan Selvanathan, Kiera Batten, Katherine Lewis, Janelle Nisbet, Ashleigh Mitchell, Troy Dalkeith, Kate Billmore, Francesca Moore, Adviye Ayper Tolun, Beena Devanapalli, Drago Bratkovic, Cathie Hilditch, Yusof Rahman, Michel Tchan, and Kaustuv Bhattacharya. Treatment of hmg-coa lyase deficiency—longitudinal data on clinical and nutritional management of 10 australian cases. Nutrients, 15:531, Jan 2023. URL: https://doi.org/10.3390/nu15030531, doi:10.3390/nu15030531. This article has 17 citations.

7. (gauthier2013aliverspecificdefect pages 1-2): Nicolas Gauthier, Jiang Wei Wu, Shu Pei Wang, Pierre Allard, Orval A. Mamer, Lawrence Sweetman, Ann B. Moser, Lisa Kratz, Fernando Alvarez, Yves Robitaille, François Lépine, and Grant A. Mitchell. A liver-specific defect of acyl-coa degradation produces hyperammonemia, hypoglycemia and a distinct hepatic acyl-coa pattern. PLoS ONE, 8:e60581, Jul 2013. URL: https://doi.org/10.1371/journal.pone.0060581, doi:10.1371/journal.pone.0060581. This article has 25 citations and is from a peer-reviewed journal.

8. (jennings2024factorsaffectingnonenzymatic pages 11-12): Elizabeth A. Jennings, Megan M. Macdonald, Irina Romenskaia, Hao Yang, Grant A. Mitchell, and Robert O. Ryan. Factors affecting non-enzymatic protein acylation by trans-3-methylglutaconyl coenzyme a. Metabolites, 14:421, Jul 2024. URL: https://doi.org/10.3390/metabo14080421, doi:10.3390/metabo14080421. This article has 2 citations.

9. (silveira20243hydroxy3methylglutaricaciddisrupts pages 5-9): Josyane de Andrade Silveira, Manuela Bianchin Marcuzzo, Jaqueline Santana da Rosa, Nathalia Simon Kist, Chrístofer Ian Hernandez Hoffmann, Andrey Soares Carvalho, Rafael Teixeira Ribeiro, André Quincozes-Santos, Carlos Alexandre Netto, Moacir Wajner, and Guilhian Leipnitz. 3-hydroxy-3-methylglutaric acid disrupts brain bioenergetics, redox homeostasis, and mitochondrial dynamics and affects neurodevelopment in neonatal wistar rats. Biomedicines, 12:1563, Jul 2024. URL: https://doi.org/10.3390/biomedicines12071563, doi:10.3390/biomedicines12071563. This article has 4 citations.

10. (silveira20243hydroxy3methylglutaricaciddisrupts pages 1-2): Josyane de Andrade Silveira, Manuela Bianchin Marcuzzo, Jaqueline Santana da Rosa, Nathalia Simon Kist, Chrístofer Ian Hernandez Hoffmann, Andrey Soares Carvalho, Rafael Teixeira Ribeiro, André Quincozes-Santos, Carlos Alexandre Netto, Moacir Wajner, and Guilhian Leipnitz. 3-hydroxy-3-methylglutaric acid disrupts brain bioenergetics, redox homeostasis, and mitochondrial dynamics and affects neurodevelopment in neonatal wistar rats. Biomedicines, 12:1563, Jul 2024. URL: https://doi.org/10.3390/biomedicines12071563, doi:10.3390/biomedicines12071563. This article has 4 citations.

11. (silveira20243hydroxy3methylglutaricaciddisrupts media cdb163bd): Josyane de Andrade Silveira, Manuela Bianchin Marcuzzo, Jaqueline Santana da Rosa, Nathalia Simon Kist, Chrístofer Ian Hernandez Hoffmann, Andrey Soares Carvalho, Rafael Teixeira Ribeiro, André Quincozes-Santos, Carlos Alexandre Netto, Moacir Wajner, and Guilhian Leipnitz. 3-hydroxy-3-methylglutaric acid disrupts brain bioenergetics, redox homeostasis, and mitochondrial dynamics and affects neurodevelopment in neonatal wistar rats. Biomedicines, 12:1563, Jul 2024. URL: https://doi.org/10.3390/biomedicines12071563, doi:10.3390/biomedicines12071563. This article has 4 citations.

12. (silveira20243hydroxy3methylglutaricaciddisrupts media f967e15a): Josyane de Andrade Silveira, Manuela Bianchin Marcuzzo, Jaqueline Santana da Rosa, Nathalia Simon Kist, Chrístofer Ian Hernandez Hoffmann, Andrey Soares Carvalho, Rafael Teixeira Ribeiro, André Quincozes-Santos, Carlos Alexandre Netto, Moacir Wajner, and Guilhian Leipnitz. 3-hydroxy-3-methylglutaric acid disrupts brain bioenergetics, redox homeostasis, and mitochondrial dynamics and affects neurodevelopment in neonatal wistar rats. Biomedicines, 12:1563, Jul 2024. URL: https://doi.org/10.3390/biomedicines12071563, doi:10.3390/biomedicines12071563. This article has 4 citations.

13. (silveira20243hydroxy3methylglutaricaciddisrupts media cd280ab9): Josyane de Andrade Silveira, Manuela Bianchin Marcuzzo, Jaqueline Santana da Rosa, Nathalia Simon Kist, Chrístofer Ian Hernandez Hoffmann, Andrey Soares Carvalho, Rafael Teixeira Ribeiro, André Quincozes-Santos, Carlos Alexandre Netto, Moacir Wajner, and Guilhian Leipnitz. 3-hydroxy-3-methylglutaric acid disrupts brain bioenergetics, redox homeostasis, and mitochondrial dynamics and affects neurodevelopment in neonatal wistar rats. Biomedicines, 12:1563, Jul 2024. URL: https://doi.org/10.3390/biomedicines12071563, doi:10.3390/biomedicines12071563. This article has 4 citations.

14. (devanapalli2023useofsodium pages 7-10): Beena Devanapalli, Adviye Ayper Tolun, Won-Tae Kim, Tiffany Wotton, Susan Thompson, and Shanti Balasubramaniam. Use of sodium d, l-3-hydroxybutyrate as adjunct therapy in two siblings with hmg-coa lyase deficiency. Journal of Translational Genetics and Genomics, 7:186-95, Sep 2023. URL: https://doi.org/10.20517/jtgg.2023.12, doi:10.20517/jtgg.2023.12. This article has 0 citations.

15. (thompson2023treatmentofhmgcoa pages 4-5): Susan Thompson, Ashley Hertzog, Arthavan Selvanathan, Kiera Batten, Katherine Lewis, Janelle Nisbet, Ashleigh Mitchell, Troy Dalkeith, Kate Billmore, Francesca Moore, Adviye Ayper Tolun, Beena Devanapalli, Drago Bratkovic, Cathie Hilditch, Yusof Rahman, Michel Tchan, and Kaustuv Bhattacharya. Treatment of hmg-coa lyase deficiency—longitudinal data on clinical and nutritional management of 10 australian cases. Nutrients, 15:531, Jan 2023. URL: https://doi.org/10.3390/nu15030531, doi:10.3390/nu15030531. This article has 17 citations.

16. (thompson2023treatmentofhmgcoa pages 6-8): Susan Thompson, Ashley Hertzog, Arthavan Selvanathan, Kiera Batten, Katherine Lewis, Janelle Nisbet, Ashleigh Mitchell, Troy Dalkeith, Kate Billmore, Francesca Moore, Adviye Ayper Tolun, Beena Devanapalli, Drago Bratkovic, Cathie Hilditch, Yusof Rahman, Michel Tchan, and Kaustuv Bhattacharya. Treatment of hmg-coa lyase deficiency—longitudinal data on clinical and nutritional management of 10 australian cases. Nutrients, 15:531, Jan 2023. URL: https://doi.org/10.3390/nu15030531, doi:10.3390/nu15030531. This article has 17 citations.

1. Disease Information

Overview

3-Hydroxy-3-methylglutaric aciduria (HMGCLD) is a rare inborn error of ketone body synthesis and leucine degradation. It was first described in the 1970s and belongs to the broader category of organic acidurias. The deficient enzyme, HMG-CoA lyase, cleaves 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) into acetoacetate and acetyl-CoA in the mitochondrial matrix. This reaction is the terminal step in leucine catabolism and the final enzymatic step in the ketogenesis pathway. Consequently, enzyme deficiency leads to both impaired leucine degradation (with accumulation of upstream metabolites) and impaired ketone body production (inability to generate the alternative fuel source during fasting).

As described by Grünert et al. (2017): "3-Hydroxy-3-methylglutaryl-coenzyme A lyase deficiency (HMGCLD) is a rare inborn error of ketone body synthesis and leucine degradation, caused by mutations in the HMGCL gene" (PMID: 28583327).

Key Identifiers

Synonyms and Alternative Names

• HMG-CoA lyase deficiency
• HMGCLD
• 3-Hydroxy-3-methylglutaryl-CoA lyase deficiency
• 3-HMG-CoA lyase deficiency
• Hydroxymethylglutaric aciduria
• HL deficiency
• 3-HMG aciduria
• 3-Hydroxy-3-methylglutaricaciduria

Information Sources

Information is derived from aggregated disease-level resources (OMIM, Orphanet, GeneReviews, HPO, ClinVar) supplemented by published case series, cohort studies, and individual patient reports in the peer-reviewed literature.

2. Etiology

Disease Causal Factors

HMGCLD is exclusively a genetic disorder. The primary cause is biallelic (homozygous or compound heterozygous) loss-of-function mutations in the HMGCL gene located on chromosome 1p36.11. The gene encodes a 325-amino acid mitochondrial protein (UniProt: P35914) that functions as a homodimer.

Genetic Risk Factors

• Causal gene: HMGCL (HGNC:5005; OMIM gene: 613898)
• Pathogenic variants: 147 classified pathogenic/likely pathogenic variants in ClinVar
• Founder mutations:
• R41Q (c.122G>A): Found in 89% of Saudi alleles. Zayed et al. (2006) reported: "We detected the common missense mutation R41Q in 89% of the tested alleles (64 alleles). 2 alleles carried the frame shift mutation F305fs (-2) and the last two alleles had a novel splice site donor IVS6+1G>A mutation" (PMID: 17173698)
• Codons 41 and 42 are mutational hotspots, accounting for 26% of all mutant alleles in one large study (PMID: 9463337)
• In the Chinese population, c.122G>A (R41Q) is also the most prevalent pathogenic variant (PMID: 41872807)
• Consanguinity is a major risk factor, particularly in populations with high rates of consanguineous marriage (Saudi Arabia, other Middle Eastern and North African populations). A Saudi retrospective cohort of 62 patients highlights the high prevalence in consanguineous populations (PMID: 35646072)

Environmental Risk Factors

While the disease is fundamentally genetic, environmental triggers precipitate acute metabolic decompensation: - Fasting (the most critical trigger — impaired ketogenesis cannot provide alternative fuel) - Intercurrent infections with fever and catabolism - High-protein diet (excessive leucine intake) - Surgical or physiological stress (PMID: 41156202) - Pregnancy and labor (PMID: 26997609; PMID: 28220407)

COVID-19 infection has been documented as a trigger for metabolic decompensation in at least one HMGCLD patient (PMID: 34329521).

Protective Factors

• Early diagnosis (especially via newborn screening) is the most significant protective factor
• Dietary management with protein/leucine restriction and fat restriction
• L-carnitine supplementation to enhance organic acid excretion
• Avoidance of prolonged fasting
• Emergency protocols during intercurrent illness (glucose infusion, sodium D,L-3-hydroxybutyrate)

Gene-Environment Interactions

The disease manifests through a gene-environment interaction model: the genetic defect creates vulnerability, but acute clinical crises are precipitated by environmental stressors (fasting, infection, catabolism). Patients can remain stable between crises with appropriate environmental management. As noted: "the therapeutical [approach] is mainly preventive and allows a very good prognosis for this disease" (PMID: 19932602). The lack of genotype-phenotype correlation further suggests that "the clinical course of HMGCLD cannot be predicted accurately from HMGCL genotype" (PMID: 28583327), implying that environmental factors and modifiers significantly influence outcome.

3. Phenotypes

Core Clinical Phenotypes

Very Frequent Phenotypes (99-80% of patients)

Frequent Phenotypes (79-30% of patients)

Occasional Phenotypes (29-5% of patients)

Very Rare Phenotypes (<5% of patients)

Phenotype Characteristics

Age of onset: Approximately 50% present in the neonatal period (first 5 days of life) and 76.5% are diagnosed during infancy. A Chinese cohort study reported: "76.5% were diagnosed during infancy, while 35.3% were identified through newborn screening protocols. Acute metabolic disturbances were reported in 88.2% of patients" (PMID: 41872807). In the largest European cohort: "In 50% of the patients, the disorder manifested neonatally, mostly within the first days of life. Only 8% of patients presented after one year of age" (PMID: 28583327). Late-onset forms exist, with presentations documented as late as adulthood, including a case of head tremor and extensive white matter changes in an adult female (PMID: 34573903), and a late-onset case in a 3-year-old (PMID: 19932602).

Symptom progression: Episodic with acute crises superimposed on a background that may be normal or show progressive neurological decline. Between episodes, patients can be asymptomatic. However, each decompensation episode risks cumulative neurological damage. White matter abnormalities may persist and progress even between crises (PMID: 28396157).

Quality of life impact: Significant. Dietary restrictions, need for emergency vigilance during illness, frequent hospitalizations, and potential developmental delays substantially affect daily functioning. Approximately 50% of patients develop some degree of psychomotor deficit.

4. Genetic/Molecular Information

Causal Gene

• Gene: HMGCL (3-hydroxymethyl-3-methylglutaryl-CoA lyase, mitochondrial)
• HGNC ID: HGNC:5005
• NCBI Gene ID: 3155
• Ensembl: ENSG00000117305
• Chromosomal location: 1p36.11 (complement: 23,801,885-23,825,429 on GRCh38)
• OMIM Gene: 613898
• Transcript: NM_000191.3

Protein

• UniProt: P35914
• Length: 325 amino acids (34,360 Da)
• Structure: Homodimer (disulfide-linked); can form homotetramers
• Subcellular localization: Mitochondrial matrix (primary); also peroxisome
• Pfam domain: HMGL-like
• Crystal structures: PDB 2CW6 (2.10 Å), 3MP3, 3MP4, 3MP5
• AlphaFold: AF-P35914
• Catalytic reaction: (3S)-3-hydroxy-3-methylglutaryl-CoA → acetoacetate + acetyl-CoA
• Tissue expression: Highest in liver; expressed in pancreas, kidney, intestine, testis, fibroblasts, lymphoblasts; very low in brain and skeletal muscle

Pathogenic Variants

Total in ClinVar: 147 pathogenic/likely pathogenic variants

Key mutations and their characteristics:

Functional consequences: All pathogenic variants cause loss of function. Recombinant enzyme studies demonstrated that "all four missense mutations in codons 41 and 42 cause a marked decrease in HL activity" (PMID: 9463337). Codons 41 and 42 are critical for catalytic function and "account for a disproportionate 21 (26%) of 82 of mutant alleles" in a large cohort.

Germline origin: All variants are germline (no somatic involvement), consistent with this being a constitutional genetic disorder.

Genotype-phenotype correlation: Absent. Grünert et al. (2017) concluded: "In agreement with previous reports, no clear genotype-phenotype correlation could be found" (PMID: 28583327). This implies environmental factors, modifier genes, and timing of metabolic stressors play significant roles in clinical outcome.

Modifier Genes

No specific modifier genes have been identified. The lack of genotype-phenotype correlation and variable phenotypic expression despite identical genotypes (especially in consanguineous populations) suggest genetic modifiers exist but remain uncharacterized.

Epigenetic Information

No disease-specific epigenetic modifications have been reported for HMGCLD.

Chromosomal Abnormalities

A 64.5 kb contiguous gene deletion at 1p36.11 encompassing HMGCL exons 1-6, FUCA1, and CNR2 has been reported, causing concurrent HMGCLD and fucosidosis (PMID: 41636194). This is the first reported case of combined fucosidosis and HMG-CoA lyase deficiency resulting from a contiguous gene deletion.

5. Environmental Information

Environmental Factors

HMGCLD is a purely genetic disorder with no environmental causative factors. However, environmental stressors are critical modulators of disease expression:

• Fasting: The single most important precipitant. Impaired ketogenesis means the body cannot produce ketone bodies as alternative fuel during glucose depletion.
• Febrile illness: Increases metabolic demand and catabolism, triggering leucine breakdown and accumulation of toxic metabolites.
• Gastrointestinal illness: Vomiting and diarrhea cause both fasting and dehydration.
• Surgical stress: Perioperative considerations are critical (PMID: 41156202).
• Pregnancy/labor: Documented trigger for metabolic decompensation. "Stress of pregnancy and labor and delivery can lead to metabolic decompensation in HMG-CoA lyase deficiency" (PMID: 26997609).

Lifestyle Factors

• Diet: High-protein and high-leucine diets exacerbate the metabolic defect. Fat-restricted diets reduce dependence on fatty acid oxidation and ketogenesis.
• Feeding patterns: Prolonged intervals between meals are dangerous, especially in infants and young children.
• Exercise: Strenuous exercise may precipitate catabolism, though this is less well documented.

Infectious Agents

No pathogen directly causes HMGCLD, but any infectious illness can precipitate metabolic decompensation. COVID-19 has been specifically documented as a trigger in an HMGCLD patient who "presented clinical and biochemical findings of an acute metabolic attack" (PMID: 34329521).

6. Mechanism / Pathophysiology

Molecular Pathways

The primary biochemical defect involves two interconnected pathways:

1. Leucine catabolism pathway (KEGG: hsa00280 — Valine, leucine and isoleucine degradation):

Leucine → α-ketoisocaproate → isovaleryl-CoA → 3-methylcrotonyl-CoA →
3-methylglutaconyl-CoA → HMG-CoA → [BLOCKED] → acetoacetate + acetyl-CoA

2. Ketogenesis pathway (KEGG: hsa00072 — Synthesis and degradation of ketone bodies):

Acetyl-CoA → acetoacetyl-CoA → HMG-CoA → [BLOCKED] → acetoacetate → 3-hydroxybutyrate

Causal Chain (Upstream → Downstream)

HMGCL gene mutation (upstream)
       ↓
HMG-CoA lyase enzyme deficiency (EC 4.1.3.4)
       ↓
   ┌───┴───────────────────┐
   ↓                       ↓
Blocked leucine         Blocked ketogenesis
catabolism              (no ketone body production)
   ↓                       ↓
Accumulation of         Hypoketotic hypoglycemia
toxic organic acids     during fasting
   ↓                       ↓
┌──┴──────────┐         Energy failure in brain
↓             ↓         and other organs
Oxidative     Direct        ↓
stress        toxicity   Neurological damage
   ↓             ↓      (seizures, coma)
Mitochondrial  Hepato-
dysfunction    toxicity
   ↓
White matter damage
Basal ganglia injury

Oxidative Stress Mechanism

The accumulated organic acids — particularly 3-hydroxy-3-methylglutarate, 3-methylglutarate, 3-methylglutaconate, and 3-hydroxyisovalerate — disrupt cellular redox homeostasis. Ribeiro et al. (2015) established that "recent animal and human in vitro and in vivo studies have suggested that oxidative stress caused by the major accumulating organic acids may represent a pathomechanism of brain and liver damage in HL deficiency" (PMID: 26041581).

Brain Metabolite Accumulation

Brain MR spectroscopy has directly demonstrated accumulation of toxic metabolites in the central nervous system. Couce et al. (2017) showed that "brain abnormal peaks in patients were formally identified to be those of 3-hydroxyisovaleric, 3-methylglutaconic, 3-methylglutaric and 3-hydroxy-3-methylglutaric acids" (PMID: 28396157). The same study noted that "Mild to extended abnormal white matter MRI signals were observed in all cases".

Metabolic Changes

Accumulating metabolites:

Deficient metabolites:

Secondary metabolic disturbances: Lactic acidosis, hyperammonemia (impaired urea cycle during crisis), secondary carnitine deficiency.

Protein Dysfunction

HMGCL protein dysfunction is primarily loss of function: - Missense mutations at the catalytic site (codons 41-42) directly abolish enzymatic activity - Nonsense and frameshift mutations produce truncated, non-functional proteins - Splice site mutations lead to aberrant mRNA processing - The enzyme normally functions as a homodimer in the mitochondrial matrix

Cellular Processes Involved

• GO:0006552 — Leucine catabolic process (directly impaired)
• GO:0016573 — Ketone body biosynthetic process (directly impaired)
• GO:0006979 — Response to oxidative stress (secondarily activated)
• GO:0006915 — Apoptosis (downstream consequence in neurons)
• GO:0007005 — Mitochondrial organization (disrupted)
• GO:0006631 — Fatty acid metabolic process (secondarily affected)

Cell Types Involved

• CL:0000182 — Hepatocyte (primary metabolic site, liver damage, ketogenesis site)
• CL:0000540 — Neuron (energy failure target)
• CL:0000128 — Oligodendrocyte (white matter damage)
• CL:0002063 — Astrocyte (supportive metabolic role)
• CL:0002306 — Kidney epithelial cell (organic acid excretion)

Tissue Damage Mechanisms

1. Oxidative stress: Organic acid-induced disruption of redox balance, particularly affecting mitochondrial function
2. Energy failure: Hypoketotic hypoglycemia deprives the brain of its primary alternative fuel source
3. Excitotoxicity: Secondary to energy failure in neurons
4. Demyelination: White matter damage from both direct toxicity and energy failure in oligodendrocytes
5. Hepatic steatosis: Lipid accumulation in hepatocytes from impaired fat metabolism
6. Reye syndrome-like episodes: Acute hepatic failure with encephalopathy during severe crises

Immune System Involvement

No primary immune dysfunction. However, intercurrent infections are the most common triggers for metabolic crises, and the catabolic state induced by infection precipitates the metabolic block's clinical consequences.

Molecular Profiling

No comprehensive transcriptomic, proteomic, or multi-omics studies have been specifically published for HMGCLD patient tissues. Metabolomic profiling has been performed primarily in the context of newborn screening optimization, identifying "3-methylglutaconic acid and 3-hydroxy-3-methylglutaric acid, together with 3-hydroxyisovalerylcarnitine as the most discriminating metabolites" between patients and controls (PMID: 32685354).

Connection to Mitochondrial Oxidative Stress

The Sod2 mutant mouse (mitochondrial superoxide dismutase knockout) provides a key mechanistic link: "The Sod2 mutant mice exhibit a tissue-specific inhibition of the respiratory chain enzymes... inactivation of the tricarboxylic acid cycle enzyme aconitase, development of a urine organic aciduria in conjunction with a partial defect in 3-hydroxy-3-methylglutaryl-CoA lyase" with "features reminiscent of... 3-hydroxy-3-methylglutaryl-CoA lyase deficiency" (PMID: 9927656). This suggests a potential positive feedback loop between HMG-CoA lyase deficiency, organic acid accumulation, oxidative stress, and further mitochondrial dysfunction.

7. Anatomical Structures Affected

Organ Level

Body systems involved: Nervous system (primary), digestive/hepatic system (primary), metabolic/endocrine system (primary), cardiovascular system (rare).

Tissue and Cell Level

• Cerebral white matter (UBERON:0002316): Abnormalities in 47.1% of patients. "Imaging revealed white matter abnormalities in 47.1% of patients and basal ganglia alterations in 17.6%" (PMID: 41872807)
• Basal ganglia (UBERON:0002420): Alterations in 17.6% of patients
• Hepatic parenchyma (UBERON:0001280): Hepatomegaly, steatosis, hepatic dysfunction
• Cerebral cortex (UBERON:0000956): Cortical atrophy in some patients

Subcellular Level

• Mitochondrial matrix (GO:0005759): Primary site of the enzymatic defect; HMG-CoA lyase is a mitochondrial matrix enzyme
• Peroxisome (GO:0005777): HMGCL also localizes to peroxisomes; potential role in peroxisomal fatty acid metabolism
• Cytoplasm (GO:0005737): Accumulation of organic acid intermediates

Localization

• Central nervous system: Bilateral, diffuse white matter involvement; basal ganglia may be affected
• Liver: Diffuse involvement
• Disease effects are bilateral and systemic during metabolic crises

8. Temporal Development

Onset

• Typical age of onset: Neonatal (50%) to infantile (76.5% diagnosed during infancy)
• HPO onset term: HP:0003593 (Infantile onset)
• Onset pattern: Acute metabolic crisis, often triggered by the physiological fasting that occurs during the first days of life
• Late-onset forms: Documented up to adulthood — a case at 3 years (PMID: 19932602), at 5 years (PMID: 38567177), and an adult female with head tremor and white matter changes (PMID: 34573903)

Progression

• Disease course: Episodic acute crises superimposed on a chronic condition
• Between episodes: Patients may be clinically stable with appropriate dietary management
• Cumulative damage: Each metabolic decompensation episode risks progressive neurological injury
• Duration: Chronic, lifelong condition requiring ongoing management
• Progression rate: Variable; depends on frequency and severity of metabolic crises and quality of chronic management
• With treatment: Many patients stabilize and frequency of crises decreases with age

Critical Periods

• Neonatal period (first 5 days): Highest risk for initial presentation due to physiological fasting and catabolism
• Infancy/early childhood: Frequent intercurrent illnesses create repeated risk of decompensation
• Pregnancy/labor: Documented metabolic stress period requiring careful monitoring. "Stress of pregnancy and labor and delivery can lead to metabolic decompensation in HMG-CoA lyase deficiency" (PMID: 26997609)
• Adolescence/adulthood: Risk persists; decompensation documented in adolescents and adults. "Patients with HL deficiency can develop hypoglycemic crises and neurological symptoms even in adolescents and adults" (PMID: 24706027)

9. Inheritance and Population

Inheritance Pattern

• Mode: Autosomal recessive (HP:0000007)
• Penetrance: Complete for biochemical phenotype (all biallelic mutation carriers show enzymatic deficiency); clinical expressivity is highly variable
• Expressivity: Highly variable — no genotype-phenotype correlation
• Genetic anticipation: Not applicable
• Germline mosaicism: Not specifically reported but theoretically possible

Epidemiology

• Worldwide prevalence: <1 per 100,000; classified as ultra-rare
• Orphanet classification: Prevalence <1/1,000,000 in most populations
• Estimated prevalence at birth: Portugal ~1:1,250,000; United States and China <1:1,000,000
• Saudi Arabia: Significantly higher due to R41Q founder mutation and consanguinity
• Netherlands NBS data (2007-2023): Screening detected multiple cases over 17 years (PMID: 40937535)
• Fewer than 200 cases reported globally in the literature

Population Demographics

Founder effects: - Saudi Arabia: R41Q accounts for 89% of pathogenic alleles. "All mutations were present in a homozygous state, reflecting extensive consanguinity" (PMID: 17173698) - China: c.122G>A is also the most prevalent variant (PMID: 41872807)

Consanguinity role: Significant, especially in Saudi Arabia and other Middle Eastern populations where the disease is most frequently observed.

Sex ratio: No sex predilection (autosomal recessive).

Geographic distribution: Worldwide, but higher prevalence in Saudi Arabia and the Arabian Peninsula, Mediterranean populations, Turkey, and South Asia — all areas with elevated consanguinity rates.

10. Diagnostics

Clinical Tests

Laboratory Tests

Urine organic acids (gold standard for biochemical diagnosis): - Elevated: 3-hydroxy-3-methylglutaric acid, 3-methylglutaconic acid, 3-methylglutaric acid, 3-hydroxyisovaleric acid, 3-methylcrotonylglycine - HP:0410051 (Increased level of 3-hydroxy-3-methylglutaric acid in urine)

Blood acylcarnitines (tandem mass spectrometry): - Elevated C5-OH (3-hydroxyisovalerylcarnitine) — primary NBS marker - Elevated C6DC (adipoylcarnitine/3-methylglutarylcarnitine)

Blood chemistry during crisis: - Hypoglycemia with absent/low ketone bodies (hypoketotic hypoglycemia) - Metabolic acidosis with elevated anion gap - Hyperammonemia - Elevated lactate (variable) - Elevated hepatic transaminases

Enzyme assay: - HMG-CoA lyase activity in cultured fibroblasts or leukocytes - HP:6000216 (Reduced HMG-CoA lyase activity in cultured fibroblasts) — found in 13/13 tested patients (PMID: 28583327)

Biomarkers

• Primary diagnostic: C5-OH acylcarnitine (blood), 3-hydroxy-3-methylglutaric acid (urine)
• Discriminating metabolites: "3-methylglutaconic acid and 3-hydroxy-3-methylglutaric acid, together with 3-hydroxyisovalerylcarnitine as the most discriminating metabolites" (PMID: 32685354)
• Monitoring: Plasma amino acids (leucine), urine organic acids, carnitine levels

Imaging Studies

• Brain MRI: White matter signal abnormalities (47.1%), basal ganglia alterations (17.6%), leukoencephalopathy (PMID: 41872807)
• Brain MR spectroscopy: Abnormal peaks corresponding to accumulating organic acids — directly confirmed in 5 patients (PMID: 28396157)
• Liver ultrasound: Hepatomegaly, steatosis

Electrophysiology

• EEG: Abnormalities including hypsarrhythmia in some patients

Newborn Screening

HMGCLD is included on the Recommended Uniform Screening Panel (RUSP) in the United States as a core condition (PMID: 41323099). Screening uses C5-OH as a marker in dried blood spots collected between 24-48 hours of life.

Dutch NBS performance (2007-2023): "Of the 126 neonates referred on the basis of elevated C5-OH concentrations in the Netherlands, 46 were true positive cases... resulting in a positive predictive value of 38.3% and a negative predictive value of 100%" (PMID: 40937535).

HMGCLD has notably high PPV among NBS-screened conditions: "The positive predictive value ranged from 0.07 (carnitine transporter defect) to 0.67 (HMG-CoA lyase deficiency)" (PMID: 37603033).

Limitation: C5-OH is not specific — it is also elevated in 3-methylcrotonyl-CoA carboxylase deficiency and holocarboxylase synthetase deficiency. "C5-OH concentrations of patients with different IEMs reported in the literature were insufficiently distinctive to differentiate between these diseases" (PMID: 40937535).

Second-tier testing using UHPLC-MS/MS for 3-hydroxy-3-methylglutaric acid and 3-methylglutaconic acid in dried blood spots can unequivocally confirm diagnosis (PMID: 32685354).

Genetic Testing

• Single gene testing: Sanger sequencing of HMGCL (9 exons) — first-line molecular confirmatory test
• Gene panels: Organic acidemia panels, metabolic disease panels
• Whole exome sequencing (WES): Effective for identifying novel variants (PMID: 38567177)
• Chromosomal microarray / exon array: Useful for detecting large deletions at 1p36.11 (PMID: 41636194)
• Prenatal diagnosis: Available via molecular testing in CVS or amniocentesis

Differential Diagnosis

11. Outcome / Prognosis

Survival and Mortality

• Mortality in largest European cohort: 6/37 patients (16.2%) died (PMID: 28583327)
• With comprehensive treatment (Australian cohort): "there is 100% survival in the remainder of the cases despite several having experienced life-threatening episodes" (PMID: 36771238)
• Life expectancy: Variable; with optimal management, survival into adulthood is expected, including successful pregnancies (PMID: 28220407; PMID: 26997609)

Cognitive Outcomes

Grünert et al. (2017) reported: "Half of the patients had a normal cognitive development while the remainder showed psychomotor deficits. We identified seven novel HMGCL mutations. In agreement with previous reports, no clear genotype-phenotype correlation could be found" (PMID: 28583327).

• Normal cognition: ~50% with treatment
• Global developmental delay: ~49% (17/35 patients)
• Neurological sequelae: Seizures, spasticity, ataxia in severe cases

Prognostic Factors

Complications

• Metabolic encephalopathy
• Permanent intellectual disability from severe/recurrent metabolic crises
• Epilepsy and movement disorders
• Hepatic steatosis / acute liver failure (rare)
• Dilated cardiomyopathy (rare)
• Acute pancreatitis (rare)

12. Treatment

Acute Crisis Management (MAXO:0000127 — Emergency treatment)

• Intravenous glucose: 10% dextrose at twice-maintenance rate to suppress catabolism
• Sodium D,L-3-hydroxybutyrate: Exogenous ketone body supplementation (900 mg/kg/day). "Five of nine patients have used 900 mg/kg/day of sodium D,L 3-hydroxybutyrate in combination with intravenous dextrose-containing fluids" (PMID: 36771238)
• Bicarbonate correction: For severe metabolic acidosis
• Ammonia-lowering therapy: Sodium benzoate/phenylbutyrate if needed

Long-term Dietary Management (MAXO:0000087 — Dietary modification)

• Protein restriction (MAXO:0000098): Low-protein diet to reduce leucine intake (typically 1.0-1.5 g/kg/day). "All patients have been on long-term protein restriction, and those diagnosed more recently have had additional fat restriction" (PMID: 36771238)
• Fat restriction: Reduces dependence on fatty acid oxidation/ketogenesis
• L-carnitine supplementation (CHEBI:16347): 50-100 mg/kg/day. "Long-term treatment consists in limited fasting time, continuous low protein diet and l-carnitine supplementation" (PMID: 19932602)
• Nocturnal uncooked cornstarch: Used in some pediatric patients to prevent overnight fasting hypoglycemia
• Avoidance of fasting (MAXO:0001344): Critical preventive measure with age-specific maximum fasting times
• Frequent feeding: Carbohydrate-enriched diet to provide alternative energy

Special Situations

Perioperative management: Minimization of fasting period, perioperative glucose infusion, monitoring for metabolic decompensation (PMID: 41156202).

Pregnancy management: Gradual increase in protein and carnitine supplementation; close monitoring by metabolic specialist, dietitian, and high-risk obstetrician; IV glucose during labor; avoidance of fasting (PMID: 26997609; PMID: 28220407).

Cost-Effectiveness of Screening

NBS for HMGCLD is among the most cost-effective of all screened conditions: "The incremental costs of screening ranged from $222,000 (HMG-CoA lyase deficiency) to $142,500,000 (glutaric acidemia type II) per LY gained" (PMID: 17391418).

Advanced Therapeutics

• Gene therapy: No approved gene therapy available. The well-defined single-gene etiology and mitochondrial target make HMGCLD a potential candidate for future liver-directed gene therapy approaches.
• Liver transplantation: Considered for severe cases (liver is primary ketogenesis site), but not established as standard treatment.
• No RNA-based therapies, cell therapies, or targeted molecular therapies are currently available or in clinical trials.

Supportive and Rehabilitative Care

• Developmental support and early intervention for neurodevelopmental delays
• Physical therapy, occupational therapy, speech therapy as needed (MAXO:0000451)
• Nutritional counseling and dietary management
• Genetic counseling for families (MAXO:0000079)
• Emergency protocols (emergency letters/cards) for metabolic crises
• Psychological support for chronic disease management

Treatment Strategy Summary

1. Newborn screening → early identification
2. Immediate dietary modification → protein and fat restriction
3. L-carnitine supplementation → improve organic acid excretion
4. Fasting avoidance → frequent meals, cornstarch at night
5. Emergency protocol during illness → aggressive IV glucose, exogenous ketone bodies
6. Long-term monitoring → urine organic acids, amino acids, carnitine levels, neurodevelopmental assessment

13. Prevention

Primary Prevention

• Genetic counseling (MAXO:0000079): For at-risk families, especially in populations with high consanguinity. 25% recurrence risk per pregnancy in carrier parents.
• Carrier screening: Especially relevant in Saudi Arabia. "Our findings have direct implications on rapid molecular diagnosis, prenatal and pre-implantation diagnosis and population based prevention programs" (PMID: 17173698)
• Prenatal diagnosis: Available via molecular testing in CVS or amniocentesis
• Pre-implantation genetic diagnosis (PGD): Available for families with known mutations

Secondary Prevention (Early Detection)

• Newborn screening (MAXO:0000118): HMGCLD is on the RUSP in the United States and included in NBS programs in the Netherlands, China, Australia, and many other countries
• Marker: Elevated C5-OH on acylcarnitine profile
• Second-tier testing improves specificity (PMID: 32685354)
• Enables pre-symptomatic treatment initiation
• Cascade testing: Testing siblings and extended family of affected individuals

Tertiary Prevention

• Fasting avoidance: Strict adherence to maximum fasting times by age
• Sick-day protocols: Emergency plans for intercurrent illness
• Emergency letters/cards: Carried by patients/families for acute care settings
• Regular metabolic follow-up: Monitoring of growth, development, metabolite levels
• Pregnancy management: Close monitoring by metabolic specialist team (PMID: 26997609)
• COVID-19 vigilance: IEM patients are vulnerable to metabolic decompensation during infection (PMID: 34329521)

14. Other Species / Natural Disease

Orthologous Genes

Natural Disease in Other Species

HMGCLD has not been widely reported as a naturally occurring disease in companion animals or livestock. The leucine catabolism and ketogenesis pathways are fundamental to mammalian metabolism, and the enzyme is highly conserved across vertebrates.

OMIA (Online Mendelian Inheritance in Animals): No specific entry confirmed for naturally occurring HMG-CoA lyase deficiency.

Comparative Biology

The Sod2 knockout mouse provides indirect evidence of evolutionary conservation: oxidative stress alone can impair HMG-CoA lyase function in mice, producing "features reminiscent of... 3-hydroxy-3-methylglutaryl-CoA lyase deficiency" (PMID: 9927656). A contiguous gene deletion at 1p36.11 involving HMGCL, FUCA1, and CNR2 demonstrates the genomic architecture is conserved, and large deletions can produce combined phenotypes (PMID: 41636194).

Zoonotic Potential

Not applicable — HMGCLD is a non-infectious genetic disorder.

15. Model Organisms

Available Models

Genetic Models

No dedicated Hmgcl knockout mouse has been widely characterized in the published literature. This represents a significant gap for preclinical research.

Model Characteristics

• Sod2-/- mouse: Partially recapitulates organic aciduria and mitochondrial dysfunction but through an oxidative stress mechanism rather than direct enzyme deficiency
• Patient fibroblasts: Can measure enzyme activity and confirm pathogenicity of variants but cannot model systemic crises
• Recombinant protein studies: Essential for structure-function analysis but limited to enzymatic characterization

Research Applications

• Fibroblast enzyme assays for diagnostic confirmation
• Recombinant protein studies for functional characterization of novel variants
• Rat brain/liver studies for understanding pathomechanisms of metabolite toxicity
• Development and validation of improved NBS strategies

Key Findings (Expanded)

Finding 1: HMGCL Gene Mutations Cause Dual Metabolic Block in Ketogenesis and Leucine Catabolism

HMGCLD results from biallelic loss-of-function mutations in the HMGCL gene (1p36.11), encoding a 325-amino acid mitochondrial enzyme (UniProt P35914). The enzyme sits at a critical metabolic junction — the terminal step of both leucine catabolism and ketogenesis. This dual role explains the disease's characteristic biochemical signature: accumulation of leucine degradation intermediates combined with an inability to produce ketone bodies during fasting. With 147 catalogued pathogenic variants spanning missense, nonsense, frameshift, splice-site, and large deletion types, the disease shows substantial allelic heterogeneity. The R41Q founder mutation predominates in Saudi Arabia (89% of alleles), while codons 41-42 collectively account for 26% of all known mutant alleles globally, indicating a catalytic hotspot critical for enzymatic function. In the Chinese population, R41Q is also the most prevalent variant. Despite this genetic diversity, no genotype-phenotype correlation exists, meaning that clinical severity cannot be predicted from the specific mutation.

Supporting evidence: - "3-Hydroxy-3-methylglutaryl-coenzyme A lyase deficiency (HMGCLD) is a rare inborn error of ketone body synthesis and leucine degradation, caused by mutations in the HMGCL gene" (PMID: 28583327) - "We detected the common missense mutation R41Q in 89% of the tested alleles (64 alleles)" (PMID: 17173698) - "76.5% were diagnosed during infancy, while 35.3% were identified through newborn screening protocols. Acute metabolic disturbances were reported in 88.2% of patients" (PMID: 41872807)

Finding 2: Oxidative Stress from Accumulated Organic Acids Drives Brain and Liver Pathology

The toxic organic acids that accumulate upstream of the enzymatic block — 3-hydroxy-3-methylglutaric acid, 3-methylglutaconic acid, 3-methylglutaric acid, and 3-hydroxyisovaleric acid — are not merely biomarkers but active pathogenic mediators. In vitro and in vivo studies demonstrate that these metabolites disrupt cellular redox homeostasis, causing oxidative stress in brain and liver tissues. Brain MR spectroscopy has directly confirmed the presence of these metabolites within brain parenchyma, demonstrating that the blood-brain barrier does not fully protect the CNS from these toxic intermediates. Neuroimaging reveals white matter abnormalities in 47.1% and basal ganglia alterations in 17.6% of patients, consistent with a model of progressive neurotoxicity. The Sod2-/- mouse model provides independent evidence that oxidative stress impairs HMG-CoA lyase function, suggesting a potential positive feedback loop where enzyme deficiency leads to metabolite accumulation, which causes oxidative stress, which further impairs mitochondrial function.

Supporting evidence: - "recent animal and human in vitro and in vivo studies have suggested that oxidative stress caused by the major accumulating organic acids may represent a pathomechanism of brain and liver damage in HL deficiency" (PMID: 26041581) - "brain abnormal peaks in patients were formally identified to be those of 3-hydroxyisovaleric, 3-methylglutaconic, 3-methylglutaric and 3-hydroxy-3-methylglutaric acids" (PMID: 28396157) - "Imaging revealed white matter abnormalities in 47.1% of patients and basal ganglia alterations in 17.6%" (PMID: 41872807)

Finding 3: Variable Outcomes with ~50% Achieving Normal Cognition Under Treatment

The largest published cohort (37 patients) demonstrated that approximately half of patients achieve normal cognitive development with appropriate management, while the remaining half develop psychomotor deficits of varying severity. Mortality was 16.2% (6/37). Importantly, the Australian cohort of 10 patients achieved 100% survival with comprehensive dietary management, L-carnitine supplementation, and acute crisis protocols including sodium D,L-3-hydroxybutyrate. No genotype-phenotype correlation exists, meaning clinical outcomes are primarily determined by the quality and timeliness of medical management rather than the specific mutation. Newborn screening has emerged as a critical prognostic modifier: HMGCLD has the highest positive predictive value (0.67) among all conditions screened by C5-OH-based NBS, and early detection enables pre-symptomatic treatment initiation.

Supporting evidence: - "Half of the patients had a normal cognitive development while the remainder showed psychomotor deficits. We identified seven novel HMGCL mutations. In agreement with previous reports, no clear genotype-phenotype correlation could be found" (PMID: 28583327) - "there is 100% survival in the remainder of the cases despite several having experienced life-threatening episodes" (PMID: 36771238) - "The positive predictive value ranged from 0.07 (carnitine transporter defect) to 0.67 (HMG-CoA lyase deficiency)" (PMID: 37603033)

Mechanistic Model / Interpretation

Integrated Pathophysiological Model

HMGCLD can be understood through a two-hit model:

Hit 1 — Chronic metabolic vulnerability: The constitutional enzyme deficiency creates a baseline state of impaired leucine handling and absent ketogenic capacity. Even between crises, patients accumulate low levels of toxic organic acids and are unable to produce ketone bodies. This baseline vulnerability manifests as restricted dietary tolerance, limited fasting capacity, and subtle ongoing metabolite-mediated tissue damage.

Hit 2 — Acute metabolic decompensation: Physiological stress (fasting, infection, catabolism) tips the metabolic balance into crisis. Three pathogenic mechanisms converge: 1. Energy failure — Without ketone bodies, the brain loses its primary alternative fuel during hypoglycemia 2. Acute metabolite toxicity — Rapid accumulation of leucine-derived organic acids during catabolism 3. Oxidative damage — Metabolite-driven redox disruption in mitochondria, particularly affecting neurons and hepatocytes

This model explains several clinical observations: - Variable expressivity without genotype-phenotype correlation: Outcomes depend on the frequency and management of acute crises, not the specific mutation - White matter predilection: Oligodendrocytes are particularly vulnerable to both energy failure and oxidative stress - Effectiveness of dietary management: Reducing leucine intake and preventing fasting addresses both hits - Value of exogenous ketone body therapy: Sodium D,L-3-hydroxybutyrate directly compensates for the ketogenic defect - Lifelong vulnerability: Even adults can decompensate during metabolic stress (pregnancy, infection, surgery)

Evidence Base

Key Supporting Literature

Ontology Summary

Key Terms for Knowledge Base Population

Limitations and Knowledge Gaps

1. Limited cohort sizes: Even the largest published series includes only 37-62 patients, limiting statistical power for subgroup analyses and genotype-phenotype correlation studies.

2. Absence of genotype-phenotype correlation: Despite over 147 known variants, no reliable predictors of disease severity or outcome have been identified, making prognostic counseling challenging.

3. Incomplete understanding of long-term outcomes: Most published data focus on pediatric outcomes. Adult natural history data are sparse, and long-term neurocognitive trajectories are insufficiently characterized.

4. Oxidative stress mechanism needs further elucidation: While the role of oxidative stress is established, the specific molecular targets, signaling pathways, and potential therapeutic interventions targeting this mechanism remain incompletely defined.

5. No specific animal model: A dedicated Hmgcl knockout mouse model with full phenotypic characterization has not been extensively published, limiting preclinical research.

6. Therapeutic limitations: Current treatment is purely supportive/preventive. No enzyme replacement therapy, gene therapy, or substrate reduction therapy has been developed.

7. NBS specificity challenges: The C5-OH marker has significant overlap between true and false positives, and between different C5-OH-related disorders, necessitating second-tier testing.

8. Lack of molecular profiling data: No transcriptomic, proteomic, or comprehensive metabolomic studies from patient tissues have been published, limiting systems-level understanding.

9. Pregnancy management data limited: Only a handful of pregnancies have been reported, with variable outcomes.

10. No formal quality of life studies: Disease-specific QoL instruments and formal QoL assessments have not been published for HMGCLD patients.

Proposed Follow-up Experiments / Actions

High Priority

1. International patient registry: Establish a centralized, prospective HMGCLD registry to collect standardized longitudinal data on genotype, treatment protocols, neurocognitive outcomes, and quality of life across the lifespan. This is the single most impactful action for improving knowledge of this ultra-rare disease.

2. Hmgcl knockout mouse model: Generate and fully characterize a conditional Hmgcl knockout mouse (liver-specific and global) to study tissue-specific pathophysiology, test therapeutic interventions, and identify biomarkers of disease progression.

3. Multi-omics profiling: Conduct transcriptomic, proteomic, and metabolomic analyses on patient-derived fibroblasts, iPSC-derived hepatocytes, and available biobank samples to identify novel therapeutic targets and prognostic biomarkers.

Medium Priority

1. Antioxidant therapy trials: Based on the established role of oxidative stress, investigate whether mitochondria-targeted antioxidants (idebenone, MitoQ, N-acetylcysteine) can reduce metabolite-mediated tissue damage — initially in cell models, then in animal models.

2. Improved NBS algorithms: Develop and validate multi-analyte NBS algorithms incorporating second-tier metabolites (3-HMG acid, 3-MGA) to improve screening specificity and reduce false-positive rates across diverse populations.

3. Gene therapy feasibility study: Evaluate AAV-mediated liver-directed gene therapy in animal models, leveraging the liver as the primary ketogenic organ. HMGCLD is an attractive gene therapy target due to its monogenic nature and the possibility that restoring liver expression alone may correct the most dangerous aspect (ketogenesis failure).

4. Adult outcome and pregnancy study: Retrospective/prospective study of adult HMGCLD patients to characterize long-term neurocognitive outcomes, reproductive health, and management during pregnancy.

Lower Priority

1. Modifier gene identification: Whole-genome sequencing in phenotypically discordant sibling pairs or large cohorts to identify genetic modifiers of disease severity that explain the variable expressivity.

2. iPSC-derived models: Generate patient-specific iPSCs, differentiate into hepatocytes and neurons, and use these for drug screening, mechanistic studies, and potential personalized therapy development.

3. Quality of life assessment: Develop and validate a disease-specific quality of life instrument for organic acidurias, including HMGCLD, to better quantify the burden of disease and evaluate treatment effectiveness.

Report generated 2026-05-05 | Based on comprehensive analysis of 29 published studies and multiple database resources (OMIM, Orphanet, ClinVar, HPO, KEGG, UniProt, PDB)